「68Ga」Ga-HTK03149 前列腺癌 PSMA 靶向 PET 显像首次人体评估
本研究为首次人体前瞻性评估,纳入10例根治性局部治疗后生化复发的前列腺癌男性,行「68Ga」Ga-HTK03149 动态及静态全身 PET/CT 显像并行剂量学计算。结果显示该示踪剂安全、血液清除快,肾脏吸收剂量最高,平均有效剂量为 0.012 ± 0.005 mSv/MBq;病灶 SUVmax 与靶/本比在 2 h 较 1 h 显著升高。
要点
- 「68Ga」Ga-HTK03149 安全,10例受试者均无不良事件。
- 肾脏吸收剂量最高(0.107 ± 0.020 mGy/MBq),平均有效剂量 0.012 ± 0.005 mSv/MBq。
- 2 h 病灶 SUVmax 与靶/本比显著优于 1 h,支持延迟显像。
核心结论
- 「68Ga」Ga-HTK03149 是安全的 PSMA 靶向 PET 放射性药物,生物分布与辐射剂量学与现有示踪剂相当。
- 其高肿瘤摄取及延迟病灶对比度改善支持进一步临床评估用于前列腺癌显像及诊疗一体化应用。
研究设计与样本
- 前瞻性首次人体研究,纳入10例根治性局部治疗后生化复发(PSA >0.4 ng/mL)的前列腺癌男性。
- 行60分钟动态 PET/CT(前6分钟聚焦心脏,随后连续全身采集),注射后1 h和2 h行静态全身采集。
- 5例受试者在1 h扫描后接受静脉呋塞米(40 mg)以评估强制利尿的影响。
- 手动勾画感兴趣体积,采用 OLINDA/EXM 2.2 版计算器官吸收剂量。
主要发现
- 10例男性(中位年龄68岁,范围61–74岁;中位 PSA 3.3 ng/mL,范围0.42–9.6 ng/mL)完成显像,无不良事件。
- 示踪剂自血液和软组织快速清除,泪腺、唾液腺、肝、脾、肾及小肠摄取明显,并经泌尿系统排泄。
- 肾脏吸收剂量最高(0.107 ± 0.020 mGy/MBq),其次为唾液腺(0.067 ± 0.019 mGy/MBq)和泪腺(0.063 ± 0.026 mGy/MBq)。
- 9/10例患者共16个病灶呈高摄取,SUVmax 1 h 为 7.13(范围5.44–10.99),2 h 为 9.52(范围7.07–13.67),P < 0.001。
- 靶/本比 1 h 为 15.74(范围10.85–21.09),2 h 为 20.42(范围12.50–27.51),P < 0.001。
关键数值与推荐
- 平均有效剂量为 0.012 ± 0.005 mSv/MBq。
- 强制利尿显著降低膀胱壁剂量(0.029 ± 0.0097 vs. 0.056 ± 0.0268 mGy/MBq,P = 0.04),但未影响肾脏剂量(P = 0.99)。
- 病灶 SUVmax 2 h 较 1 h 显著升高(9.52 vs. 7.13,P < 0.001),靶/本比亦显著升高(20.42 vs. 15.74,P < 0.001)。
临床怎么用
- 「68Ga」Ga-HTK03149 PET/CT 可用于前列腺癌生化复发患者的病灶显像,2 h 延迟显像可提高病灶对比度。
- 基于其生物分布与剂量学特征,可考虑用于 PSMA 靶向诊疗一体化评估。
- 对需降低膀胱壁剂量的患者,可考虑在注射后1 h给予呋塞米强制利尿(不影响肾脏剂量)。
局限性
- 样本量小(10例),为首次人体评估。
- 仅纳入生化复发患者,未涉及初诊分期或治疗反应评估人群。
- 强制利尿仅在5例受试者中实施。
- 随访与长期安全性数据未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Prostate-specific membrane antigen (PSMA) is a validated target for prostate cancer imaging and therapy. [68Ga]Ga-HTK03149 is a PSMA inhibitor designed to improve biodistribution by incorporating a 2-aminoadipic acid moiety as an alternative PSMA binding group. We report the first-in-human safety, biodistribution, and dosimetry evaluation of [68Ga]Ga-HTK03149 and explore organ uptake relevant to future theranostic use. Methods: Men with biochemical recurrence of prostate cancer (prostate-specific antigen, >0.4 ng/mL) after definitive local therapy were enrolled. Each participant underwent a 60-min dynamic PET/CT scan (heart-focused for the first 6 min and then serial whole-body passes), followed by static whole-body acquisitions at 1 and 2 h after injection. In 5 participants, intravenous furosemide (40 mg) was given after the 1-h scan. Volumes of interest were drawn manually, and organ absorbed doses were calculated using OLINDA/EXM version 2.2. Results: Ten men (median age, 68 y; range, 61-74 y; median prostate-specific antigen, 3.3 ng/mL; range, 0.42-9.6 ng/mL) completed imaging without adverse events. Vital signs and laboratory parameters showed no clinically relevant changes. [68Ga]Ga-HTK03149 cleared rapidly from blood and soft tissue, with prominent uptake in the lacrimal and salivary glands, liver, spleen, kidneys, and small intestine, as well as urinary excretion. The kidneys received the highest absorbed dose (0.107 ± 0.020 mGy/MBq), followed by the salivary glands (0.067 ± 0.019 mGy/MBq) and lacrimal glands (0.063 ± 0.026 mGy/MBq). The mean effective dose was 0.012 ± 0.005 mSv/MBq. Forced diuresis significantly reduced the urinary bladder wall dose (0.029 ± 0.0097 vs. 0.056 ± 0.0268 mGy/MBq, P = 0.04) but did not affect the kidney dose (P = 0.99). Lesions (n = 16 in 9/10 patients) showed high uptake and improved contrast at 2 h, with an SUVmax of 7.13 (range, 5.44-10.99) at 1 h versus 9.52 (range, 7.07-13.67) at 2 h (P < 0.001) and a tumor-to-background ratio of 15.74 (range, 10.85-21.09) at 1 h versus 20.42 (range, 12.50-27.51) at 2 h (P < 0.001). Conclusion: [68Ga]Ga-HTK03149 is a safe PSMA-targeted PET radiopharmaceutical with biodistribution and radiation dosimetry comparable to those of existing tracers. Its high tumor uptake and improved delayed lesion contrast support further clinical evaluation for prostate cancer imaging and theranostic applications.
引用
- Chaussé G, Hou X, Uribe C, et al. First-in-Human Evaluation of [68Ga]Ga-HTK03149, a PSMA-Targeted Tracer for PET Imaging in Prostate Cancer. J Nucl Med. 2026. PMID: 41748290. doi:10.2967/jnumed.123.266357
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。